Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancerShunichi Sugawara, Kazuhiko Nakagawa, Naoki Inui et al.|Annals of Oncology|2021Cited by 202
LBA54 Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLCJS Lee, Kazuhiko Nakagawa, Shunichi Sugawara et al.|Annals of Oncology|2020Cited by 14